1-9 of 9
The German CLL Study Group
Close
Sort by
Journal Articles

Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis

Clinical Trials & Observations
Barbara F. Eichhorst, Kirsten Fischer, Anna-Maria Fink, Thomas Elter, Clemens M. Wendtner, Valentin Goede, Manuela Bergmann, Stephan Stilgenbauer, Georg Hopfinger, Matthias Ritgen, Jasmin Bahlo, Raymonde Busch, Michael Hallek, for the German CLL Study Group (GCLLSG)
Journal: Blood
Blood (2011) 117 (6): 1817–1821.
https://doi.org/10.1182/blood-2010-04-282228
Published: 2011
Includes: Supplemental data
Journal Articles

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

Clinical Trials & Observations
Peter Dreger, Hartmut Döhner, Matthias Ritgen, Sebastian Böttcher, Raymonde Busch, Sascha Dietrich, Donald Bunjes, Sandra Cohen, Jörg Schubert, Ute Hegenbart, Dietrich Beelen, Matthias Zeis, Michael Stadler, Justin Hasenkamp, Lutz Uharek, Christof Scheid, Andreas Humpe, Thorsten Zenz, Dirk Winkler, Michael Hallek, Michael Kneba, Norbert Schmitz, Stephan Stilgenbauer, for the German CLL Study Group
Journal: Blood
Blood (2010) 116 (14): 2438–2447.
https://doi.org/10.1182/blood-2010-03-275420
Published: 2010
Includes: Supplemental data
Journal Articles

Bendamustine Combined with Rituximab (BR) in First-Line Therapy of Advanced CLL: A Multicenter Phase II Trial of the German CLL Study Group (GCLLSG).

Kirsten Fischer, MD, Paula Cramer, MD, Stephan Stilgenbauer, MD, Raymonde Busch, Leopold Balleisen, MD, Julia Kilp, MD, Anna-Maria Fink, MD, Sebastian Boettcher, MD, Matthias Ritgen, MD, Michael Kneba, MD, PhD, Peter Staib, MD, Hartmut Döhner, MD, Silke Schulte, Barbara F. Eichhorst, MD, Michael Hallek, MD, Clemens-Martin Wendtner, MD, the German CLL Study Group (GCLLSG)
Journal: Blood
Blood (2009) 114 (22): 205.
https://doi.org/10.1182/blood.V114.22.205.205
Published: 2009
Journal Articles

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

Clinical Trials & Observations
Barbara F. Eichhorst, Raymonde Busch, Stephan Stilgenbauer, Martina Stauch, Manuela A. Bergmann, Matthias Ritgen, Nicole Kranzhöfer, Robert Rohrberg, Ulrike Söling, Oswald Burkhard, Anne Westermann, Valentin Goede, Carmen D. Schweighofer, Kirsten Fischer, Anna-Maria Fink, Clemens M. Wendtner, Günter Brittinger, Hartmut Döhner, Bertold Emmerich, Michael Hallek, the German CLL Study Group (GCLLSG)
Journal: Blood
Blood (2009) 114 (16): 3382–3391.
https://doi.org/10.1182/blood-2009-02-206185
Published: 2009
Includes: Supplemental data
Journal Articles

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG)

Kirsten Fischer, MD, Stephan Stilgenbauer, MD, Carmen D Schweighofer, MD, Raymonde Busch, Jasmin Renschler, Michael Kiehl, MD, Leopold Balleisen, MD, Michael J Eckart, MD, Anna- Maria Fink, MD, Julia Kilp, MD, Matthias Ritgen, MD, Sebastian Böttcher, MD, Michael Kneba, MD, PhD, Hartmut Döhner, MD, Barbara F Eichhorst, MD, Michael Hallek, MD, Clemens- Martin Wendtner, MD, The German CLL Study Group
Journal: Blood
Blood (2008) 112 (11): 330.
https://doi.org/10.1182/blood.V112.11.330.330
Published: 2008
Journal Articles

Dose Escalation Study To Evaluate Dose Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and Safety of Alemtuzumab for Consolidation Therapy in Patients with Chronic Lymphoycytic Leukemia: Phase I/II Trial of the German CLL Study Group (GCLLSG).

Kirsten Fischer, MD, Carmen D. Schweighofer, MD, Matthias Ritgen, MD, Sebastian Boettcher, MD, Elena Scharf, Barbara F. Eichhorst, MD, Raymonde Busch, Wolfgang Abenhardt, MD, Michael Kneba, MD, Michael Hallek, MD, Clemens-Martin Wendtner, MD, the German CLL Study Group (GCLLSG)
Journal: Blood
Blood (2007) 110 (11): 2053.
https://doi.org/10.1182/blood.V110.11.2053.2053
Published: 2007
Journal Articles

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG).

Kirsten Fischer, MD, Stephan Stilgenbauer, MD, Carmen D. Schweighofer, MD, Jasmin Renschler, Raymonde Busch, Michael Kiehl, MD, Leopold Balleisen, MD, Michael Eckart, MD, Anna M. Fink, MD, Sebastian Boettcher, MD, Matthias Ritgen, MD, Michael Kneba, MD, Peter Staib, MD, Hartmut Doehner, MD, Barbara F. Eichhorst, MD, Michael Hallek, MD, Clemens-Martin Wendtner, MD, the German CLL Study Group (GCLLSG)
Journal: Blood
Blood (2007) 110 (11): 3106.
https://doi.org/10.1182/blood.V110.11.3106.3106
Published: 2007
Journal Articles

Consolidation with Alemtuzumab Improves Progression-Free Survival in Patients with Chronic Lymphocytic Leukemia (CLL) in First Remission - Long-Term Follow-Up of a Randomized Phase III Trial of the German CLL Study Group (GCLLSG).

C. Schweighofer, M. Ritgen, B. Eichhorst, R. Busch, M. Kneba, M. Hallek, Clemens Wendtner, the German CLL Study Group
Journal: Blood
Blood (2006) 108 (11): 33.
https://doi.org/10.1182/blood.V108.11.33.33
Published: 2006
Journal Articles

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

Clinical Trials & Observations
Barbara F. Eichhorst, Raymonde Busch, Georg Hopfinger, Rita Pasold, Manfred Hensel, Cordelia Steinbrecher, Siegfried Siehl, Ulrich Jäger, Manuela Bergmann, Stephan Stilgenbauer, Carmen Schweighofer, Clemens M. Wendtner, Hartmut Döhner, Günter Brittinger, Bertold Emmerich, Michael Hallek, the German CLL Study Group
Journal: Blood
Blood (2006) 107 (3): 885–891.
https://doi.org/10.1182/blood-2005-06-2395
Published: 2006